Eurofins Scientific (ERF) | Financial Analysis & Statements
Eurofins Scientific SE | Large-cap | Healthcare
Eurofins Scientific SE | Large-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
7.0B
Gross Profit
4.7B
67.79%
Operating Income
726.2M
10.45%
Net Income
405.5M
5.83%
EPS (Diluted)
€2.09
Balance Sheet Metrics
Total Assets
10.9B
Total Liabilities
5.5B
Shareholders Equity
5.4B
Debt to Equity
1.02
Cash Flow Metrics
Operating Cash Flow
855.6M
Free Cash Flow
790.5M
Revenue & Profitability Trend
Eurofins Scientific Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7.0B | 6.5B | 6.7B | 6.7B | 5.4B |
| Cost of Goods Sold | 2.2B | 2.2B | 2.2B | 2.1B | 1.7B |
| Gross Profit | 4.7B | 4.4B | 4.5B | 4.6B | 3.7B |
| Operating Expenses | 46.0M | 50.3M | 16.4M | 38.2M | 21.6M |
| Operating Income | 726.2M | 546.8M | 783.2M | 1.3B | 805.5M |
| Pre-tax Income | 554.6M | 423.3M | 780.0M | 1.1B | 694.4M |
| Income Tax | 149.1M | 115.5M | 174.2M | 273.6M | 153.9M |
| Net Income | 405.5M | 307.8M | 605.8M | 783.0M | 540.5M |
| EPS (Diluted) | €2.09 | €1.57 | €3.07 | €3.90 | €2.75 |
Income Statement Trend
Eurofins Scientific Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 2.5B | 3.1B | 2.3B | 2.3B | 2.5B |
| Non-Current Assets | 8.4B | 7.8B | 7.8B | 7.0B | 6.1B |
| Total Assets | 10.9B | 10.9B | 10.1B | 9.3B | 8.6B |
| Liabilities | |||||
| Current Liabilities | 2.1B | 2.1B | 1.8B | 1.9B | 1.7B |
| Non-Current Liabilities | 3.4B | 3.6B | 3.5B | 2.8B | 3.2B |
| Total Liabilities | 5.5B | 5.8B | 5.2B | 4.7B | 4.9B |
| Equity | |||||
| Total Shareholders Equity | 5.4B | 5.1B | 4.9B | 4.7B | 3.7B |
Balance Sheet Composition
Eurofins Scientific Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 554.6M | 423.3M | 780.0M | 1.1B | 694.4M |
| Operating Cash Flow | 855.6M | 655.9M | 1.1B | 1.3B | 778.4M |
| Investing Activities | |||||
| Capital Expenditures | -443.4M | -471.7M | -561.2M | -419.6M | -305.6M |
| Investing Cash Flow | -787.8M | -622.6M | -775.8M | -952.3M | -482.8M |
| Financing Activities | |||||
| Dividends Paid | -95.6M | -191.9M | -192.1M | -130.4M | -500.0K |
| Financing Cash Flow | -780.5M | 677.5M | -95.4M | -588.1M | 169.8M |
| Free Cash Flow | 790.5M | 467.8M | 476.1M | 1.0B | 868.0M |
Cash Flow Trend
Eurofins Scientific Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.48
Forward P/E
17.15
Price to Book
2.56
Price to Sales
1.52
PEG Ratio
17.15
Profitability Ratios
Profit Margin
5.85%
Operating Margin
12.98%
Return on Equity
7.71%
Return on Assets
5.15%
Financial Health
Current Ratio
1.16
Debt to Equity
67.05
Beta
0.79
Per Share Data
EPS (TTM)
€2.09
Book Value per Share
€23.23
Revenue per Share
€36.47
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| erf | 10.6B | 28.48 | 2.56 | 7.71% | 5.85% | 67.05 |
| bioMérieux S.A | 14.2B | 32.96 | 3.37 | 10.68% | 10.86% | 11.65 |
| Lumibird S.A | 353.3M | 61.73 | 1.78 | 2.91% | 2.71% | 81.34 |
| Eurofins Cerep SAS | 103.9M | 14.33 | - | 10.49% | 17.67% | 0.46 |
| Klea Holding | 53.9M | 17.87 | 1.92 | 5.35% | 8.14% | 21.13 |
| Predilife S.A | 13.9M | - | - | -4,653.75% | 97.76% | -1.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.